LIPO-202 + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Abdominal Bulging
Conditions
Central Abdominal Bulging
Trial Timeline
Jun 1, 2015 → Feb 26, 2016
NCT ID
NCT02483533About LIPO-202 + Placebo
LIPO-202 + Placebo is a phase 3 stage product being developed by Evofem Biosciences for Central Abdominal Bulging. The current trial status is terminated. This product is registered under clinical trial identifier NCT02483533. Target conditions include Central Abdominal Bulging.
What happened to similar drugs?
4 of 19 similar drugs in Central Abdominal Bulging were approved
Approved (4) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02483533 | Phase 3 | Terminated |
| NCT02398188 | Phase 3 | Completed |
Competing Products
20 competing products in Central Abdominal Bulging